RxDoctor Payments Data

Sonia Dhawan, MD

Internal Medicine · Pittsburgh, PANPI 1639169352

Payments from drug & device makers

$611in general payments, 2019–2025

Across 9 payments — averaging $67.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$130
  • Amgen$125
  • Boehringer Ingelheim$120
  • Regeneron Healthcare Solutions, Inc.$108
  • Vivus LLC$61
  • Pfizer$26
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,431
Medicare patients
209
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$66,199
OzempicSemaglutide60$65,351
MounjaroTirzepatide39$56,724
JanuviaSitagliptin Phosphate45$39,396
TrulicityDulaglutide31$36,277
JardianceEmpagliflozin26$22,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,767
Spiriva HandihalerTiotropium Bromide11$12,470
Breo ElliptaFluticasone/Vilanterol29$12,369
MyrbetriqMirabegron14$6,916
Tresiba Flextouch U-100Insulin Degludec12$5,863
Tiotropium Bromide11$4,831
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$4,365
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$4,244
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$66,19980 claims
GSKTrelegy Ellipta, Breo Ellipta$19$27,13647 claims
Boehringer IngelheimJardiance$120$22,72726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →